semaglutide heart issues cardiovascular outcomes align more closely with attained dose than achieved weight loss Recent study at UC Irvine

Semaglutide is well-tolerated, with minor side effects such as morning nausea and occasional vomiting [20]

More serious risks are rare but can include complications such as inflammation of the pancreas or gallbladder problems

The impact of GLP-1 adoption on protein isnt one trend but at least four running in parallel: a demand shift, a capacity race, a pricing model breakdown, and a durability question, each with a different time horizon and each moving prices in its own way

Once you stop, the food noise can return, and you can be at risk of gaining the weight you just worked so hard to lose

GLP 1 receptor agonists and dual incretin therapies are delivering measurable, outcome driven results: 12% to 27% relative risk reduction in major adverse cardiovascular events across CVOTs 13% to 14% reduction in cardiovascular death in meta analyses 11% to 14% reduction in hospitalization for heart failure 24% relative risk reduction in kidney outcomes in the dedicated FLOW trial with semaglutide Up to 15.8% weight loss with semaglutide 2.4 mg 20.2% weight loss with tirzepatide 15 mg in head to head obesity trials 66% to 93% reduction in progression from prediabetes to type 2 diabetes This is no longer about glucose (or weight loss) alone